Literature DB >> 27656490

Endobronchial Inflammatory Myofibroblastic Tumour-A Case Report.

Vishnukanth Govindaraj1, Debasis Gochhait2, Balla Nagamalli Kumar3, Suryakala Narayanasami4.   

Abstract

Lung malignancies are on the rise and sadly present at an advanced stage. Fiberoptic bronchoscopy is used for staging as well as in diagnosis of lung malignancies. However, not all endobronchial growth are malignant. Inflammatory Myofibroblastic Tumour (IMT) is one of the rare tumours of the lung. A controversy regarding the benign versus malignant nature of the tumour is still ongoing. The management of these tumours can be challenging because there are no established treatment protocols. Although IMT most commonly arises from lung, endobronchial presentation is very rare. We report a case of endobronchial presentation of IMT and discuss about its aetiology and treatment options.

Entities:  

Keywords:  Fiberoptic bronchoscopy; Inflammatory pseudotumour; Lung malignancies; Smooth muscle antigen

Year:  2016        PMID: 27656490      PMCID: PMC5028533          DOI: 10.7860/JCDR/2016/20776.8270

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  13 in total

1.  Inflammatory pseudotumour of the lung.

Authors:  Youri Kaitoukov; George Rakovich; Sylvain Trahan; Jocelyn Grégoire
Journal:  Can Respir J       Date:  2011 Nov-Dec       Impact factor: 2.409

2.  Regression of inflammatory myofibroblastic tumor of the gastrointestinal tract under infliximab treatment.

Authors:  Georgios Germanidis; Ioannis Xanthakis; Ioannis Tsitouridis; Thomas Zaramboukas; Dimitrios Kiskinis; Christos Konstantaras; Spiros Miliaras; Theodoros Sirakos; Emmanouil Pagkalos
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

3.  IgG4-positive plasma cells in inflammatory pseudotumor (plasma cell granuloma) of the lung.

Authors:  Yoh Zen; Satoshi Kitagawa; Hiroshi Minato; Hiroshi Kurumaya; Kazuyoshi Katayanagi; Shinji Masuda; Hideki Niwa; Masaki Fujimura; Yasuni Nakanuma
Journal:  Hum Pathol       Date:  2005-07       Impact factor: 3.466

4.  Myofibroblastic tumours: neoplasias with divergent behaviour. Ultrastructural and flow cytometric analysis.

Authors:  R Biselli; R Boldrini; C Ferlini; C Boglino; A Inserra; C Bosman
Journal:  Pathol Res Pract       Date:  1999       Impact factor: 3.250

5.  Successful combination chemotherapy for metastatic inflammatory myofibroblastic tumor: A case report.

Authors:  Kyoko Inadomi; Hozumi Kumagai; Kotoe Takayoshi; Hiroshi Ariyama; Hitoshi Kusaba; Akihiro Nishie; Hidetaka Yamamoto; Ken Takase; Mamoru Tanaka; Kosuke Sagara; Yuta Okumura; Kenta Nio; Michitaka Nakano; Shuji Arita; Yoshinao Oda; Koichi Akashi; Eishi Baba
Journal:  Oncol Lett       Date:  2015-09-16       Impact factor: 2.967

6.  Inflammatory myofibroblastic tumor successfully treated with chemotherapy and nonsteroidals: a case report.

Authors:  Yun-Lu Tao; Zhen-Jun Wang; Jia-Gang Han; Ping Wei
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

Review 7.  Successful treatment of inflammatory myofibroblastic tumor with malignant transformation by surgical resection and chemotherapy.

Authors:  Megan K Dishop; Brad W Warner; Louis P Dehner; Vesna M Kriss; Martha F Greenwood; John D Geil; Jeffrey A Moscow
Journal:  J Pediatr Hematol Oncol       Date:  2003-02       Impact factor: 1.289

8.  Inflammatory myofibroblastic tumor.

Authors:  Sangeeta Palaskar; Supriya Koshti; Mahesh Maralingannavar; Anirudha Bartake
Journal:  Contemp Clin Dent       Date:  2011-10

9.  A rare benign tumor of the lung: Inflammatory myofibroblastic tumor - Case report.

Authors:  Ozkan Demirhan; Selvinaz Ozkara; Mustafa Yaman; Kamil Kaynak
Journal:  Respir Med Case Rep       Date:  2013-02-04

10.  An Unusual Case of Systemic Inflammatory Myofibroblastic Tumor with Successful Treatment with ALK-Inhibitor.

Authors:  Sanjivini V Jacob; John D Reith; Angerika Y Kojima; William D Williams; Chen Liu; Lizette Vila Duckworth
Journal:  Case Rep Pathol       Date:  2014-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.